Compare Ecolab Inc. (ECL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Summit Therapeutics Inc — how do they compare? Ecolab Inc. trades at $281.83 (market cap $78.97B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Ecolab Inc. is far larger — about 5.8× Summit Therapeutics Inc's market cap, and Ecolab Inc. pays a 1.04% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Summit Therapeutics Inc for 16 Days on average.
| ECL | SMMT | |
|---|---|---|
Market Cap | $78.97B | $13.71B |
Volume | 974,947 | 6,173,057 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $26.38 |
52-Week Low | $245.73 | $12.43 |
Typical Hold Time | 90 Days | 16 Days |
Enterprise Value | $87.75B | $13.04B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $281.83, up 1.34% today, with strong analyst support (78% buy ratings) and a $326.38 consensus price target. The stock shows bullish technical momentum above key support at $279, while fundamentals reveal steady revenue growth to $16.08B in 2025 and robust profitability with 12.57% net margins. Recent Q2 earnings beat expectations, and the company maintains dividend aristocrat status with consistent payout increases.
Outlook remains positive given ECL's essential service contracts, digital segment growth, and high institutional ownership. Key risks include rising debt from the $4.75B CoolIT acquisition and cost inflation pressures. The stock offers a compelling growth-and-income profile for investors seeking exposure to defensive industrial services with recurring revenue streams.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
